Cibc World Markets Corp Purchases Shares of 5,454 Twist Bioscience Co. (NASDAQ:TWST)

Cibc World Markets Corp acquired a new position in Twist Bioscience Co. (NASDAQ:TWST) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 5,454 shares of the company’s stock, valued at approximately $253,000.

Other institutional investors have also recently made changes to their positions in the company. Van ECK Associates Corp increased its stake in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience during the third quarter worth about $34,000. US Bancorp DE raised its stake in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares during the period. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience in the 3rd quarter worth approximately $95,000. Finally, KBC Group NV boosted its stake in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the period.

Wall Street Analysts Forecast Growth

TWST has been the subject of several research analyst reports. Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 target price on Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $44.25 on Wednesday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -13.09 and a beta of 2.15. The firm’s 50-day moving average is $45.45 and its 200 day moving average is $45.36.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the prior year, the firm posted ($0.75) earnings per share. The company’s quarterly revenue was up 24.1% on a year-over-year basis. Research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the transaction, the chief executive officer now directly owns 660,966 shares in the company, valued at $27,549,062.88. This represents a 0.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Paula Green sold 1,259 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65. Following the sale, the senior vice president now directly owns 132,014 shares of the company’s stock, valued at $6,514,890.90. This represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,799 shares of company stock worth $1,593,944 over the last quarter. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.